Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483574 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
A Phase 3 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,378
- Enrollment target
NCT00483574 is a Phase 3 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,378 participants.
The verdict
NCT00483574, a Phase 3 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,378 participants
- Enrollment target
Study Summary
This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered in the US. Safety Objective: To describe the safety profile of two doses of Menactra® Vaccine.
Interventions
- BIOLOGICAL Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- BIOLOGICAL Measles-mumps-rubella-varicella vaccine
- BIOLOGICAL Routine paediatric vaccine - Pneumococcal conjugate (PCV)
- BIOLOGICAL Routine paediatric vaccine - Hepatitis A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,378 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00483574
The ClinicalTrials.gov registry entry for NCT00483574 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,378 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate is the first listed.
NCT00483574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00483574 about?
NCT00483574 is a clinical study titled "Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers". This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered in the US. Safety Objective: To describe the safety profile of two do...
What is the current status of trial NCT00483574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,378 participants. The study started on 2007-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00483574?
The interventions under investigation include: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (BIOLOGICAL), Measles-mumps-rubella-varicella vaccine (BIOLOGICAL), Routine paediatric vaccine - Pneumococcal conjugate (PCV) (BIOLOGICAL), Routine paediatric vaccine - Hepatitis A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00483574?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.